Immutep Ltd (IMMP)

Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The firm’s shares underwent notable traction earlier this week after Indian firm Dr.

While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in the opposite direction.

In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti.

Micro-cap companies, generally referring to publicly traded businesses with less than $300 million in market capitalization, are among the most volatile and high-risk investments in the stock market.

Immutep Limited (NASDAQ:IMMP) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, the company shared that it had received positive feedback from the U.S.

Australia’s S&P/ASX 200 index advanced 0.53% on Thursday to close at 8,873.80, with investors buoyed by gains in the banking sector, amid robust earnings and renewed hopes for further interest rate ...

Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now.

While the Australian market is relatively well-positioned, it is vulnerable to broader market shocks, says SG Hiscock & Company (an Australian boutique investment manager).

The tariffs announced by the United States have challenged the economic and market outlooks around the globe.